SERPINE1 mRNA binding protein 1 pseudogene 5Genealiases: []
Q-omics provides the consensus-scored SERBP1P5 profile across patient tissues and cancer cell-line models. SERBP1P5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SERBP1P5 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, SERBP1P5 RNA expression shows 17,321 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where SERBP1P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SERBP1P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SERBP1P5 survival associations across molecular data types. SERBP1P5 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SERBP1P5 RNA expression–survival associations across cancer types. High SERBP1P5 expression shows unfavorable associations in ACC, LIHC, MESO, LGG and KIRP, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SERBP1P5 RNA expression.
This table summarizes SERBP1P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SERBP1P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SERBP1P5 shows lower tumor expression in KICH and higher tumor expression in COAD, LUSC, HNSC, LUAD and BLCA. The COAD box plot shows higher SERBP1P5 RNA expression in tumor versus normal tissue (log2 FC = +0.834, t-test p < 0.001).
This table shows molecular features associated with SERBP1P5 in patient tissues and cancer cell lines. In patient samples, SERBP1P5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
